These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
230 related items for PubMed ID: 10386113
1. Gout: beyond the stereotype. Jones RE, Ball EV. Hosp Pract (1995); 1999 Jun 15; 34(6):95-102; discussion 102-3; quiz 133. PubMed ID: 10386113 [Abstract] [Full Text] [Related]
2. New treatments for gout. Perez-Ruiz F. Joint Bone Spine; 2007 Jul 15; 74(4):313-5. PubMed ID: 17606397 [No Abstract] [Full Text] [Related]
3. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT. Clin Pharmacol Ther; 2011 Sep 15; 90(3):392-8. PubMed ID: 21796116 [Abstract] [Full Text] [Related]
4. Lesinurad/allopurinol (Duzallo) for gout-associated hyperuricemia. Med Lett Drugs Ther; 2017 Nov 06; 59(1533):182-183. PubMed ID: 29125593 [No Abstract] [Full Text] [Related]
5. Febuxostat--treatment for hyperuricemia and gout? Moreland LW. N Engl J Med; 2005 Dec 08; 353(23):2505-7. PubMed ID: 16339099 [No Abstract] [Full Text] [Related]
6. Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia. JAMA; 2018 Jan 09; 319(2):188-189. PubMed ID: 29318274 [No Abstract] [Full Text] [Related]
7. Urate oxidase (rasburicase) for treatment of severe acute gout: a case report. Wipfler-Freibmuth E, Dejaco C, Duftner C, Gaugg M, Kriessmayr-Lungkofler M, Schirmer M. Clin Exp Rheumatol; 2009 Jan 09; 27(4):658-60. PubMed ID: 19772802 [Abstract] [Full Text] [Related]
10. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy. Keith MP, Gilliland WR. Clin Pharmacol Ther; 2011 Sep 09; 90(3):363-4. PubMed ID: 21862966 [Abstract] [Full Text] [Related]
11. Allopurinol: insights from studies of dose-response relationships. Day RO, Kannangara DR, Stocker SL, Carland JE, Williams KM, Graham GG. Expert Opin Drug Metab Toxicol; 2017 Apr 09; 13(4):449-462. PubMed ID: 27927043 [Abstract] [Full Text] [Related]
13. [Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)]. Alten R, Mischkewitz M, Nitschmann S. Internist (Berl); 2020 May 09; 61(5):530-532. PubMed ID: 32130437 [No Abstract] [Full Text] [Related]
14. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. Zhang T, Pope JE. Rheumatology (Oxford); 2017 Jul 01; 56(7):1144-1153. PubMed ID: 28379501 [Abstract] [Full Text] [Related]
15. [Rasburicase for tophaceus gout treatment]. Ribeiro A, Bogas M, Costa J, Costa L, Araújo D. Acta Reumatol Port; 2009 Jul 01; 34(3):551-4. PubMed ID: 19820680 [Abstract] [Full Text] [Related]
16. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. Hosoya T, Ogawa Y, Hashimoto H, Ohashi T, Sakamoto R. J Clin Pharm Ther; 2016 Jun 01; 41(3):290-7. PubMed ID: 27109450 [Abstract] [Full Text] [Related]